Key Summary Points {#FPar1}
==================

suPAR is a non-specific marker associated with a high negative predictive value for unfavourable outcome.Levels \< 4 ng/ml allow discharge of the patient admitted to the ED after thorough clinical evaluation.Levels \> 6 ng/ml are an alarming sign of risk for unfavourable outcome but need to be interpreted in light of the patient\'s history.Levels between 4 and 6 ng/ml need to be interpreted in light of the patient\'s history of comorbidities, which may increase them, such as rheumatoid arthritis, solid tumour malignancy and chronic renal disease.Levels \> 12 ng/ml in critically ill patients are prognostic of 28-day mortality ranging between 17 and 50% depending on the APACHE II score.

Introduction {#Sec1}
============

Early risk detection is the main purpose of personnel committed to the triage of patients admitted to the emergency department (ED) of all secondary and tertiary hospitals. Successful triage may affect final outcomes. The difficulty to triage often increases when clinical signs and symptoms are subtle or unspecific. Nowadays, biomarkers are introduced to better screen the risk of death for patients with subtle or unspecific signs.

The Hellenic Sepsis Study Group (HSSG) (<https://www.sepsis.gr>) has been active since 2006 and aims to improve the early diagnosis and management of sepsis. The clinical development of surrogate tools for the definition of sepsis risk is one of the major aims of the HSSG. Since the group has shown long-term expertise in the clinical value of suPAR (soluble urokinase plasminogen activator receptor), we decided to frame a position paper on the role of suPAR in the early detection of risk of unfavourable outcome for patients admitted to the ED.

Methods {#Sec2}
=======

A panel of 16 experts who actively participate in the HSSG were called to participate. They were five intensivists (AA, DB, GD, SG, VK, DV), one cardiologist (JP), two ED physicians (IP and EP), four infectious diseases exerts (CG, EJGB, ML and AP) and four internists (ZA, NA, KL and PK) with vast ED experience. An initial e-mail invitation was sent on 17 November 2019 to all 16 experts explaining that the paper would be composed of positions on: (1) the biological role of the uPAR/suPAR and the diagnostic and prognostic utility for infectious and non-infectious disorders; (2) the diagnostic and prognostic utility of suPAR in sepsis; (3) the diagnostic utility of guiding treatment in the ED. Three members of the panel (DV, GD and EJGB) were delegated to draft the respective position statements according to their research expertise.

The panel experts met in person on 28 November 2019 where each of the three delegates presented their statement orally followed by discussion. It was decided that each statement and the main discussion points would be the core of the manuscript. The next meeting took place on 25 January 2020. Before the meeting, the manuscript draft was distributed to all members of the panel. During the meeting, all experts provided their comments and finalized the manuscript. The final published statement was a consensus of all meeting participants. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Position 1 {#Sec3}
==========

The Biological Role of the uPAR/suPAR and the Diagnostic and Prognostic Utility for Infectious and Non-Infectious Disorders {#Sec4}
---------------------------------------------------------------------------------------------------------------------------

suPAR is the soluble counterpart of urokinase plasminogen activator receptor (uPAR), which is a protein anchored to cell membranes by glycosyl-phospatidyl (GPI) moieties. uPAR is found in many immune cells, such as monocytes, activated lymphocytes and tissue macrophages, although it may also be present in fibroblasts and cardiomyocytes. uPAR has several functions and is involved in cell proliferation, angiogenesis and fibrinolysis. Under infectious and non-infectious inflammatory conditions, the GPI moiety that anchors uPAR to the cell is cleaved, and this leads to the release of suPAR. suPAR may be detected in serum, plasma, cerebrospinal fluid and urine and is a marker of disease severity. suPAR has a secondary structure of 17 anti-parallel β-sheets with 3 short α-helices. There are three homologous domains of suPAR: DI, DII and DIII. Comparing cDNA sequences, DI differs from DII and DIII in its primary and tertiary structure, yielding its distinct ligand-binding properties. We currently know that suPAR is a non-specific marker and that many conditions, both acute and chronic, may affect serum levels \[[@CR1]\].

suPAR levels have been suggested to mirror the degree of inflammation as its concentration is associated with the activation of the immune system. suPAR levels are positively correlated with pro-inflammatory biomarkers, such as tumour necrosis factor-α, leukocyte counts and C-reactive protein. It has also been associated with organ damage in various diseases. As such, elevated levels of suPAR are associated with increased risk of systemic inflammatory response syndrome (SIRS), cancer, focal segmental glomerulosclerosis, cardiovascular disease, type 2 diabetes, infectious diseases, HIV and mortality.

Over the last 20 years, evidence has accumulated (summarized in reviews \[[@CR2]--[@CR4]\]) showing that many disorders are accompanied by increased levels of suPAR. Among these diseases are chronic autoimmune disorders, solid tumour malignancies and chronic heart failure. More precisely, the activation of uPAR takes place at the level of the cell membrane of chondrocytes and osteocytes in patients with rheumatoid arthritis and mediated bone resorption \[[@CR2]\]. suPAR is increased in patients with colorectal cancer, ovarian cancer, breast cancer and prostate cancer, and it is an indicator of unfavourable prognosis \[[@CR3]\]. The implication of the uPAR/suPAR activation in malignancy is so well studied that it is even considered a novel therapeutic target \[[@CR4]\]. Understanding of the implication of suPAR as an early prognostic marker in patients with malignancy is coming from Greece. Starting from a small number of patients who comprised a derivation cohort, the prognostic value of suPAR was studied in a validation cohort of 267 patients all suffering from chronic liver disorders. Patients with active hepatocellular carcinoma (HCC) were excluded from the study. Enrolled patients were classified as low (*n* = 75) or high risk (*n* = 192) for the development of HCC according to the criteria of the European Association for the Study of the Liver. Among those at high risk, concentrations of suPAR were greater in the group of patients who eventually developed HCC within the next 7 years. A cut-off point of 9.56 ng/ml had 90.4% sensitivity and 96.4% negative predictive value for the development of HCC within the next 7 years \[[@CR5]\].

In a large-scale prospective study, patients who developed chronic renal disease were divided at the start of their follow-up into four quartiles of suPAR: \< 2.37 ng/ml (*n* = 515), between 2.37 and 3.03 ng/ml (*n* = 577), between 3.04 and 4.02 ng/ml (*n* = 601) and \> 4.02 ng/ml (*n* = 599). The rate toward decrease of the baseline glomerular filtration rate (GFR) over the first decade of follow-up was greater among patients in the last quartile. More precisely, the annual change of GFR was − 0.9 ml/min/1.73 m^2^ among patients in the first quartile and − 4.2 ml/min/1.73 m^2^ among patients in the fourth quartile \[[@CR6]\]. The same four quartiles of suPAR are also predictive of the risk of developing acute renal injury among patients who undergo coronary angiography as a result of the contrast material used during this procedure \[[@CR7]\]. The deterioration of renal function may come from the formation of complexes between suPAR and α~ν~β~3~ integrins on renal podocytes. This interaction is further enhanced among African Americans who carry the high-risk *APOL1* genotype \[[@CR8]\]. This effect on the glomeruli leading to proteinuria is consistent with the recently reported greater values of suPAR among patients with focal segmental glomerulosclerosis \[[@CR9]\].

TRIAGE III is an interventional trial in Denmark where suPAR is used to improve DEPT (Danish Emergency Process Triage) used by the ED physicians. DEPT consists of a combined assessment of vital signs and symptoms and classifies patients into categories: Red (highest risk of death the next 7 days), Orange, Yellow and Green (least risk for death the next 7 days). suPAR was measured in 4420 patients and improved the prognostic performance of DEPT by moving more patients into the Red and Orange categories so that the area under the curve for 7-day mortality (receiver-operator characteristic analysis) of suPAR combined with DEPT was 0.81 compared with 0.71 for DEPT only \[[@CR10]\]. A post-hoc analysis of the data of the TRIAGE III trial revealed that among patients who were discharged the first 24 h, the range of suPAR was between 2.6 and 4.7 ng/ml in 30-day survivors and between 6.7 and 11.8 ng/ml in 30-day non-survivors \[[@CR11]\]. These data support that concentrations of suPAR \< 4 ng/ml are interpreted as normal and allow safe patient discharge from the ED. Concentrations \> 6 ng/ml are indicative of substantial risk of death. A grey zone remains for patients with values between 4 and 6 ng/ml \[[@CR12]\].

An interesting recent publication refers to the important prognostic role of suPAR for the development of severe respiratory failure among patients admitted to the ED with pneumonia by the new coronavirus SARS-CoV-2 (COVID-19 disease). suPAR ≥ 6 ng/ml was associated with sensitivity, specificity, positive predictive value and negative predictive value of 85.7%, 91.7%, 85.7% and 91.7%, respectively, for the prediction of the progression into severe respiratory failure necessitating mechanical ventilation \[[@CR13]\].

Comment 1: The position implies that the interpretation of suPAR levels needs to be done with an individualized approach considering the history of malignancy or chronic renal disease since this may lead to increased baseline values. This, however, generates the question of the lifetime of suPAR in chronic conditions.

Position 2 {#Sec5}
==========

Diagnostic and Prognostic Utility of suPAR in Sepsis {#Sec6}
----------------------------------------------------

Two large clinical studies have been performed in Greece on the diagnostic and prognostic value of suPAR for sepsis. Both studies were conducted before 2016, so sepsis classification was done according to the 2003 criteria. The first study enrolled 180 patients with sepsis developing in the field of ventilator-associated pneumonia who were hospitalized in two Intensive Care Units (ICUs). suPAR was measured for 7 consecutive days. Concentrations were significantly greater among patients with severe sepsis and septic shock than among those with uncomplicated sepsis. When analysis was done for the prognosis of outcome, it was found that suPAR \> 12.9 ng/ml was an independent predictor of unfavourable outcome; serum levels remained stable over the disease course. suPAR was also detected in the supernatants of isolated neutrophils of the first day of symptoms, indicating this cell type as a main reservoir of production \[[@CR14]\].

The second study was multicenter and enrolled 1914 patients from 37 study sites of the HSSG; suPAR was measured in the serum in the first 24 h from the presence of signs of SIRS; in 367 patients suPAR was also measured on days 3, 7 and 10 of follow-up. Patients were stratified into four strata of severity considering suPAR and the APACHE (Acute Physiology and Chronic Health Evaluation) II score; suPAR \< 12 ng/ml and APACHE II \< 17; suPAR ≥ 12 ng/ml and APACHE II \< 17; suPAR \< 12 ng/ml and APACHE II ≥ 17; suPAR ≥ 12 ng/ml and APACHE II ≥ 17. The respective 28-day mortality was 5.5%, 17.4%, 37.4% and 51.5%; suPAR remained unchanged during follow-up of survivors and non-survivors. An independent confirmation cohort of 196 patients with severe sepsis/septic shock from Sweden was studied; the 28-day mortality for the four strata of severity was 2.0%, 28.6%, 21.3% and 33.8%, respectively \[[@CR15]\].

Comment 1: Do we have data on the suPAR clearance? Can this affect measurements and risk assessment?

Reply: Data are not available.

Position 3 {#Sec7}
==========

Clinical Research on Early Patient Management Guided by suPAR {#Sec8}
-------------------------------------------------------------

The most critical element of sepsis management is the early administration of appropriate antimicrobial therapy. This knowledge was developed from a retrospective analysis of 2713 patients in septic shock. The start of antibiotic treatment the first hour from onset of hypotension was accompanied by 79.1% survival after 28 days; each hour of delay was accompanied by a 7.6% decrease of the chances of survival \[[@CR16]\]. This mandates the early recognition of severe infection. This is easier when signs of sepsis exist and far more difficult for patients with unspecific complaints. Since the introduction of the Sepsis-3 definitions in 2016, qSOFA (quick SOFA score) has been introduced as an early warning score in the ED. qSOFA screens for the presence of tachypnoea defined as \> 22 breaths/min, mental confusion defined as Glasgow Coma Scale \< 13 and hypotension defined as systolic blood pressure \< 100 mmHg. Every patient who presents at least two of these signs has at least 10% risk of death after 28 days, whatever is defined with 90% sensitivity \[[@CR17]\]. According to recently published data of the HSSG, even patients with a qSOFA score of 1 have a significant risk for 28-day unfavourable outcome \[[@CR18]\]. This generates the question of whether suPAR may help trace the patients among those with one sign of qSOFA at significantly greater risk of death compared with those with one sign of qSOFA but without increased suPAR. This is the rationale of the SUPERIOR trial that is running in two study sites of the HSSG (EudraCT no. 2018-001008-13; ClinicalTrials.gov NCT03717350) \[[@CR19]\]. In this ongoing study, enrolled patients are adults with clinical suspicion of an infection, one sign of qSOFA and suPAR ≥ 12 ng/ml. Patients with two or three signs of qSOFA, transplanted patients, patients with full-blown sepsis and patients with no resuscitation decision are excluded. Enrolled patients are randomized to blind treatment with placebo or with one single infusion of 2 g meropenem. Then, patients are returned to the triage queue already set for them. Primary study endpoint according to the last revision of the study protocol is the early worsening of the patient defined as any at least one point increase of the admission total SOFA score in the first 24 h. Main secondary study endpoints are (1) the early worsening of the patient analyzed separately per quartile of the total SOFA score of the patient population and (2) 7-, 28-, 60- and 90-day mortality.

Comment 1: According to everyday clinical practice, pulmonary embolism is a common cause of tachypnoae. This equals 1 point of the qSOFA score. How can this be adjusted in the SUPERIOR trial?

Reply: This is why suspicion of infection is one of the inclusion criteria whereas one of the secondary endpoints is analysis among patients who eventually meet the Sepsis-3 definitions.

Comment 2: Regarding clinical practice, not the protocol per se, it needs to be emphasized that patients with 1 point of qSOFA are not septic. However, the purpose of the protocol is to identify those patients with 1 point on qSOFA who are probably at high risk of death. Proper analysis also mandates recording the time delay until the start of ED management.

Points of Discussion {#Sec9}
====================

Point 1: It is mandatory to clarify the confounding factors that may be realted to this biomarker since production may be triggered by other situations. suPAR is a non-specific marker and can only screen for the risk of unfavourable outcome without knowing what the underlying condition is. As such, it can be very useful for all patients admitted in the ED and not just for infections. I would personally favour having more research evidence on other acute conditions in the ED such as acute heart failure. I believe that the best approach is to associate cut-off concentrations of suPAR with a specific level of risk.

Point 2: In light of all that has been stated so far and taking into consideration that solid malignancies may generate higher baseline levels for patients, we believe that suPAR ≥ 12 ng/ml in oncological patients is an alarming sign of sepsis.

Point 3: We find very attractive the possibility that, among patients with one sign of qSOFA, which is usually considered non-alarming, the use of suPAR may be of considerable added value for risk definition.

Point 4: The overall negative predictive value of suPAR, whatever the detection of low levels means, probably \< 4 ng/ml, will allow the safe discharge of patients.

Point 5: In light of the very strong data for the value of suPAR as a rule-out marker, it needs to be emphasized that the biomarker still has great diagnostic validity. Looking at the same data from another point of view, there is no doubt from the clinical perspective that elevated suPAR levels in a patient with infection are compatible with sepsis.

Final Statement {#Sec10}
===============

Considering all the positions and points of discussion, the following position statement regarding the utility of suPAR for patients admitted to the ED was made:suPAR is a non-specific marker associated with a high negative predictive value for unfavourable outcome.Levels \< 4 ng/ml allow discharge of the patient admitted to the ED after thorough clinical evaluation.Levels \> 6 ng/ml are an alarming sign of risk for unfavourable outcome but they need to be interpreted in light of the patient\'s history.Levels between 4 and 6 ng/ml need to be interpreted in light of the patient\'s history of comorbidities, which may increase them, such as rheumatoid arthritis, solid tumour malignancy and chronic renal disease.Levels \> 12 ng/ml in critically ill patients are prognostic of 28-day mortality ranging between 17 and 50% depending on the APACHE II score.Levels \> 12 ng/ml in a patient with suspicion of infection and one sign of the qSOFA score may be indicative of sepsis and unfavourable outcome.No strong evidence is available yet to support the use of suPAR as a surrogate tool for antimicrobial stewardship.

Suggested Algorithm {#Sec11}
===================

It is emphasized that the diagnostic and prognostic utilities of suPAR have not been evaluated by any panel of international guidelines and that the GRADE system of recommendations has not been applied yet to validate suPAR. The panel of experts participating in this position paper ended up using an algorithm for the daily use of suPAR according to the level of patient management (ED, general ward, intensive care unit), which is presented in Fig. [1](#Fig1){ref-type="fig"} and Table [1](#Tab1){ref-type="table"} summarizing the strengths and the weaknesses of this biomarker. There are still challenges to the interpretation of both suPAR and qSOFA in the ED, which require further research. These include: (1) NPV of suPAR \< 4 ng/ml when qSOFA = 1; (2) clear-cut definitions of moderate and low risk of death as depicted in Fig. [1](#Fig1){ref-type="fig"}. On-going trials are anticipated to provide concrete answers to these questions. Table [2](#Tab2){ref-type="table"} provides a summary of the available and ongoing studies on the utility of suPAR as either a diagnostic tool or treatment guidance in the acute care setting after a search at Clinicaltrials.gov.Fig. 1Proposed algorithm for the interpretation of the values of suPAR (soluble urokinase plasminogen activator receptor) according to the level of health services. *APACHE* Acute Physiology and Chronic Health Evaluation, *ED* emergency department, *ICU* intensive care unit, *qSOFA* quick sequential organ failure assessment, *SIRS* systemic inflammatory response syndrome. \*The first 30 days. \*\*Chronic renal disease, solid malignancy, chronic infection by the human immunodeficiency virusTable 1Expert position on the strengths and weaknesses of soluble urokinase plasminogen activator receptor (suPAR) for the prognosis of patients at the emergency department (ED)ReferenceStrengths\[[@CR10]\]Concentrations \> 6 ng/ml have high sensitivity for unfavourable outcome and signify considerable risk of death for patients admitted to the ED\[[@CR11]\]Concentrations \< 4 ng/ml have high NPV for unfavourable outcome and allow discharge of the patient from the ED\[[@CR14]\]Concentrations \< 12 ng/ml for patients with infections and systemic inflammatory response syndrome have high NPV for unfavourable outcome after 28 daysReferenceLimitations\[[@CR1]\]Non-specific for certain disease entities\[[@CR3]--[@CR6]\]Comorbidities such as chronic renal disease, HIV infection, solid tumour malignancy increase baseline levels\[[@CR10]\]Concentrations between 4 and 6 ng/ml do not clearly indicate the risk of unfavourable outcome for patients admitted to the ED*HIV* human immunodeficiency virus, *NPV* negative predictive valueTable 2Available and on-going studies on the role of suPAR for diagnosis and treatment guidance in the acute care setting. Results are from a search of Clinicaltrials.govNCT numberAcronymBrief titleStatusDesignSettingTarget patientsNCT02643459TRIAGERisk stratification in acute care: the meaning of suPAR measurement in triageCompletedRandomized SOC; no suPAR suPAR knownED in two hospitals in Denmark20,000NCT03147352ProTreatPrognosis and treatment of necrotizing soft tissue infections: a prospective cohort studyCompletedIntervention with hyperbaric oxygenSurgical ward in two hospitals in Denmark260NCT03717350SUPERIORsuPAR to guide antibiotics in emergency departmentOngoingRandomized based on suPAR levels Placebo MeropenemED in two hospitals in Greece244NCT04357366SAVEsuPAR-guided anakinra treatment for validation of the risk and management of respiratory failure by COVID-19OngoingOpen-label anakinra for patients with Covid-19 and suPAR ≥ 6 ng/mlGeneral wards in 14 hospitals in Greece100NCT03249597NAPredict sepsis: the predictive values of bedside measurement in the ambulanceOngoingObservationalFour study sites in Sweden648*ED* emergency department, *NA* non-available, *SOC* standard of care
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